Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIOP Ependymoma II Program
NCT02265770Phase 3Recruiting
- Sponsor
- Centre Léon Bérard
- Start
- Jun 2015
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies, Lipid-based Nanoparticles, Orthosteric Ligands
- Countries
- 15
01
Overview
A Phase 3 trial of vincristine sulfate liposome injection, etoposide, cyclophosphamide, Cisplatin micelle injection (HA132), methotrexate in ependymoma, sponsored by Centre Léon Bérard. Started Jun 2015; status: recruiting.
02
Drugs
vincristine sulfate liposome injectionetoposidecyclophosphamideCisplatin micelle injection (HA132)methotrexate
03
Conditions
ependymoma
Beyond the preview
Go deeper on NCT02265770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02265770.